To evaluate the effect of tablet pregabalin and tablet duloxetine with tablet pregabalin and tablet nortriptyline in neuropathic pain after herpes and changes in HLA-A33 and HLA-B44 GENES.
Phase 4
- Conditions
- Health Condition 1: L089- Local infection of the skin and subcutaneous tissue, unspecified
- Registration Number
- CTRI/2020/03/024235
- Lead Sponsor
- niversity College Of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.Patients should have a diagnosis of PHN with evident hyperalgesia and allodynia.
2. Patients of PHN should have pain for at least 12 weeks after the healing of rash.
3.Pain intensity >= 4 on 10 of NRS-pain scale
Exclusion Criteria
1.Patients with history of neurological intervention for PHN.
2.Evidence of other sources of chronic or acute pain that may confound the diagnosis
3. Known history of intake Pregabalin or Duloxetine for PHN in past 4 weeks.
4. Patients with past h/o MI, DM, pancreatitis and vasculitis.
5. Patients with evidence of renal impairment/history of alcohol consumption and smoking.
6.Patients with psychiatric or substance abuse disorder.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Proportion of patients achieving NRS-pain score of 4/10 at the end of 12th week in both <br/ ><br>the groups. <br/ ><br>2. The neuropathic component of pain using NPSI score in both the groups.Timepoint: At baseline and at the end of 1st week, 2nd week, 4th week, 8th week and 12th week.
- Secondary Outcome Measures
Name Time Method 1. NRS-sleep score in the two groups at various designated intervals. <br/ ><br>2. PDQ score in both the groups at various designated intervals. <br/ ><br>3. The quality of life (QoL) using SF-12 score in the two groups at various designated <br/ ><br>intervals. <br/ ><br>4. Modulation in mRNA expressions of HLA-A33 and HLA-B44 genes at baseline and after <br/ ><br>12 weeks of treatment.Timepoint: At baseline and at the end of 1st week, 2nd week, 4th week, 8th week and 12th week.